Literature DB >> 35345891

Markedly Increasing Antibiotic Resistance and Dual Treatment of Neisseria gonorrhoeae Isolates in Guangdong, China, from 2013 to 2020.

Xiaomian Lin1, Xiaolin Qin1, Xingzhong Wu1, Yiwen Liao1, Yuqi Yu1,2, Qinghui Xie3, Sanmei Tang1,2, Chixing Guo4, Junming Pei5, Zhizhou Wu6, Changhui Cai7, Feng Wang8, Shanghua Wu9, Heyong Chen10, Xiaofeng Liu11, Ming Li12, Wenling Cao13, Heping Zheng1.   

Abstract

The emergence of multidrug resistance in Neisseria gonorrhoeae is concerning, especially the cooccurrence of azithromycin resistance and decreased susceptibility to extended-spectrum cephalosporin. This study aimed to confirm the antibiotic resistance trends and provide a solution for N. gonorrhoeae treatment in Guangdong, China. A total of 5,808 strains were collected for assessment of antibiotic MICs. High resistance to penicillin (53.80 to 82%), tetracycline (88.30 to 100%), ciprofloxacin (96 to 99.8%), cefixime (6.81 to 46%), and azithromycin (8.60 to 20.03%) was observed. Remarkably, spectinomycin and ceftriaxone seemed to be the effective choices, with resistance rates of 0 to 7.63% and 2.00 to 16.18%, respectively. Moreover, the rates of azithromycin resistance combined with decreased susceptibility to ceftriaxone and cefixime reached 9.28% and 8.64%, respectively. Furthermore, genotyping identified NG-STAR-ST501, NG-MAST-ST2268, and MLST-ST7363 as the sequence types among representative multidrug-resistant isolates. Evolutionary analysis showed that FC428-related clones have spread to Guangdong, China, which might be a cause of the rapid increase in extended-spectrum cephalosporin resistance currently. Among these strains, the prevalence of N. gonorrhoeae was extremely high, and single-dose ceftriaxone treatment might be a challenge in the future. To partially relieve the treatment pressure, a susceptibility test for susceptibility to azithromycin plus extended-spectrum cephalosporin dual therapy was performed. The results showed that all the representative isolates could be effectively killed with the coadministration of less than 1 mg/liter azithromycin and 0.125 mg/liter extended-spectrum cephalosporin, with a synergistic effect according to a fractional inhibitory concentration (FIC) of <0.5. In conclusion, dual therapy might be a powerful measure to treat refractory N. gonorrhoeae in the context of increasing antibiotic resistance in Guangdong, China.

Entities:  

Keywords:  FC428; N. gonorrhoeae; dual therapy; genotyping; resistance

Mesh:

Substances:

Year:  2022        PMID: 35345891      PMCID: PMC9017359          DOI: 10.1128/aac.02294-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  39 in total

Review 1.  Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.

Authors:  Magnus Unemo; William M Shafer
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Australian Gonococcal Surveillance Programme Annual Report, 2019.

Authors:  Monica M Lahra; Masoud Shoushtari; C R Robert George; Benjamin H Armstrong; Tiffany R Hogan
Journal:  Commun Dis Intell (2018)       Date:  2020-07-15

3.  High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes.

Authors:  Stephanie A Chisholm; Jayshree Dave; Catherine A Ison
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

4.  Resistance to Ceftriaxone and Azithromycin in Neisseria gonorrhoeae Isolates From 7 Countries of South America and the Caribbean: 2010-2011.

Authors:  Sidharath Dev Thakur; Pamela Araya; Graciela Borthagaray; Patricia Galarza; Alina Llop Hernandez; Daisy Payares; Olga Marina Sanabria Cruz; Maria Elena Trigoso Carvallo; Aura Helena Corredor; Jo-Anne R Dillon
Journal:  Sex Transm Dis       Date:  2017-03       Impact factor: 2.830

5.  Identification of amino acids conferring high-level resistance to expanded-spectrum cephalosporins in the penA gene from Neisseria gonorrhoeae strain H041.

Authors:  Joshua Tomberg; Magnus Unemo; Makoto Ohnishi; Christopher Davies; Robert A Nicholas
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

6.  New Ceftriaxone- and Multidrug-Resistant Neisseria gonorrhoeae Strain with a Novel Mosaic penA Gene Isolated in Japan.

Authors:  Shu-Ichi Nakayama; Ken Shimuta; Kei-Ichi Furubayashi; Takuya Kawahata; Magnus Unemo; Makoto Ohnishi
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

7.  Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011.

Authors:  Catherine A Ison; Katy Town; Chinelo Obi; Stephanie Chisholm; Gwenda Hughes; David M Livermore; Catherine M Lowndes
Journal:  Lancet Infect Dis       Date:  2013-06-11       Impact factor: 25.071

8.  Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae.

Authors:  Lai-King Ng; Irene Martin; Gary Liu; Louis Bryden
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

9.  Determining the in vitro susceptibility of Neisseria gonorrhoeae isolates from 8 cities in Guangdong Province through an improved microdilution method.

Authors:  Xingzhong Wu; Xiaolin Qin; Jinmei Huang; Feng Wang; Ming Li; Zhizhou Wu; Xiaofeng Liu; Junming Pei; Shanghua Wu; Heyong Chen; Chixing Guo; Yaohua Xue; Sanmei Tang; Mingheng Fang; Yinyuan Lan; Jiangli Ou; Zhenmou Xie; Yuqi Yu; Jieyi Yang; Wentao Chen; Yunhu Zhao; Heping Zheng
Journal:  Diagn Microbiol Infect Dis       Date:  2018-06-12       Impact factor: 2.803

10.  Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015.

Authors:  Michelle J Cole; Gianfranco Spiteri; Susanne Jacobsson; Neil Woodford; Francesco Tripodo; Andrew J Amato-Gauci; Magnus Unemo
Journal:  BMC Infect Dis       Date:  2017-09-11       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.